Cue Biopharma Clinical Trial Data
Cue Biopharma announced positive topline results from a Phase 2 clinical trial of CUE-221 in patients with moderate to severe Chronic Spontaneous Urticaria (CSU). The study met its primary endpoint of complete resolution of hives (HSS7=0) at all dose levels with high statistical significance, demonstrating superiority over placebo and showing a favorable safety profile. The company plans to advance the candidate into a Phase 2b/3 registration-enabling study based on these results.
- Counterparty
- Genesis Life Sciences
- Term
- 36 weeks